Clavero-Adell M, Palanca-Arias D, Ayerza-Casas A, López-Ramón M, Jiménez-Montañés L

Language: Spanish
References: 14
Page: 21-25
PDF size: 203.74 Kb.

ABSTRACT

Background: Dilated cardiomyopathy is the main cause of pediatric cardiac transplantation.
Clinical case: We present a four months old child (preterm birth at 29-week gestational age) affected from dilated cardiomyopathy secondary to Bordetella pertussis infection. At diagnosis there are unfavorable prognostic factors (patient age, high initial proBNP figure and left ventricular ejection fraction less than 30%). However, after 6 months of immunomodulatory treatment with ciclosporine and prednisone he presents an adequate clinical evolution.
Conclusions: Although dilated cardiomyopathy is an alteration that puts patients' lives at risk, it is worth noting the satisfactory clinical and analytical evolution and recovery of our case during the first year.

REFERENCES

1. Moonen M, et al. Update on myocarditis. Rev Med Liege 2018; 73(5-6):269-276. https://www.rmlg.ulg.ac.be/ show.php

2. Elamm C, et al. Republished: Pathogenesis and diagnosis of myocarditis. Postgrad Med J 2012; 88(1043):539- 544. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5813801/

3. Canter CE, et al. Diagnosis and treatment of myocarditis in children in the current era. Circulation 2014;7;129(1):115- 28. https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA. 113.001372

4. Towbin JA, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;18;296(15):1867- 76. DOI: 10.1001/jama.296.15.1867

5. Rodriguez-Gonzalez M, et al. Clinical presentation and early predictors for poor outcomes in pediatric myocarditis: a retrospective study. World J Clin Cases 2019;6;7(5):548- 561. DOI: 10.12998/wjcc.v7.i5.548

6. Caforio ALP, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34(33):2636-48, 2648a-2648d. doi: 10.1093/ eurheartj/eht210.

7. Campbell H, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. J Med Microbiol 2018;67(10):1426-1456. doi: 10.1099/jmm.0.000829.

8. Das BB. Role of endomyocardial biopsy for children presenting with acute systolic heart failure. Pediatr Cardiol 2014;35(2):191-6. doi: 10.1007/s00246-013-0807-0.

9. Sachdeva S, et al. Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol 201515;115(4):499-504. doi: 10.1016/j.amjcard. 2014.11.029.

10. Gagliardi MG, et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 2004;90(10):1167-71. DOI: 10.1136/hrt.2003.026641

11. Frustaci A, et al. Randomized study on the efficacy of immunosuppressive therapy in patients with virusnegative inflammatory cardiomyopathy: The TIMIC study. Eur Heart J 2009;30(16):1995-2002. doi: 10.1093/ eurheartj/ehp249

12. Hollander SA, et al. Outcomes of children following a first hospitalization for dilated cardiomyopathy. Circ Heart Fail 2012;5(4):437-43. doi: 10.1161/CIRCHEARTFAILURE. 111.964510.

13. Furuta M, et al. Efficacy and safety of pertussis vaccination for pregnant women - a systematic review of randomised controlled trials and observational studies. BMC Pregnancy Childbirth 2017;17(1):390. doi: 10.1186/ s12884-017-1559-2

14. Byrne L, et al. Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England. Arch Dis Child 2018;103(3):224-229. doi: 10.1136/archdischild-2016-311802.